Suppliers and packagers for trandolapril

trandolapril

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Rising Pharma Holdings, Inc.	57237-089-01	100 TABLET in 1 BOTTLE (57237-089-01)	2007-06-12
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Rising Pharma Holdings, Inc.	57237-090-01	100 TABLET in 1 BOTTLE (57237-090-01)	2007-06-12
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Rising Pharma Holdings, Inc.	57237-091-01	100 TABLET in 1 BOTTLE (57237-091-01)	2007-06-12
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Aurobindo Pharma Limited	65862-164-01	100 TABLET in 1 BOTTLE (65862-164-01)	2007-06-12
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Aurobindo Pharma Limited	65862-164-99	1000 TABLET in 1 BOTTLE (65862-164-99)	2007-06-12
Aurobindo Pharma	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078438	ANDA	Aurobindo Pharma Limited	65862-165-01	100 TABLET in 1 BOTTLE (65862-165-01)	2007-06-12

Trandolapril Suppliers: Market Analysis and Intellectual Property Landscape

Last updated: February 19, 2026

This report analyzes the key suppliers for trandolapril, a widely used angiotensin-converting enzyme (ACE) inhibitor, examining their manufacturing capabilities, market presence, and the intellectual property (IP) landscape surrounding its production. Understanding these elements is critical for pharmaceutical companies seeking to secure reliable supply chains and navigate the competitive environment.

What is Trandolapril and Its Therapeutic Use?

Trandolapril is a prodrug that is converted in the body to its active metabolite, trandolaprilat. Trandolaprilat is a potent ACE inhibitor. ACE inhibitors work by blocking the action of angiotensin-converting enzyme, which plays a role in regulating blood pressure. By inhibiting this enzyme, trandolapril helps to relax blood vessels, lowering blood pressure and reducing the workload on the heart.

Trandolapril is primarily prescribed for the treatment of:

• Hypertension: High blood pressure.
• Heart Failure: A condition where the heart cannot pump blood effectively.
• Post-Myocardial Infarction (Heart Attack): To improve survival rates and prevent further cardiac events in patients who have had a heart attack.

It is often formulated in combination with other cardiovascular medications, such as calcium channel blockers (e.g., verapamil). This dual-action approach can enhance blood pressure control and offer broader therapeutic benefits.

Who are the Primary Manufacturers and Suppliers of Trandolapril?

The manufacturing and supply of trandolapril involve several key entities, ranging from originator pharmaceutical companies to contract manufacturing organizations (CMOs) and generic drug producers. These suppliers are essential for ensuring the global availability of this important medication.

Key Players in Trandolapril Supply:

• Abbott Laboratories (and its former affiliate, Knoll Pharmaceuticals, now part of Abbott): Abbott was the originator of trandolapril, marketed under the brand name Mavik (in the U.S.) and Tareg. While Abbott retains significant market presence for branded products, the generic market is now dominated by other manufacturers.
• Takeda Pharmaceutical Company: Following its acquisition of Nycomed, Takeda gained rights and manufacturing capabilities for various cardiovascular drugs, potentially including trandolapril or its intermediates.
• Generic Drug Manufacturers: The expiration of key patents has led to the emergence of numerous generic manufacturers. These companies are crucial for providing affordable alternatives. Prominent generic suppliers often include companies with extensive API (Active Pharmaceutical Ingredient) manufacturing capabilities, such as:
  • Lupin Limited: A global pharmaceutical company with a strong presence in generics, often involved in the production of APIs and finished dosage forms.
  • Dr. Reddy's Laboratories: Another major Indian pharmaceutical company with significant API manufacturing and global distribution networks.
  • Sun Pharmaceutical Industries: A leading global pharmaceutical company with a broad portfolio of generic drugs.
  • Aurobindo Pharma: Known for its extensive API and finished dosage form manufacturing, with a focus on generics.
  • Cipla Limited: A long-standing Indian pharmaceutical company with a global reach in generic drug supply.

These generic manufacturers often operate sophisticated API production facilities and have established distribution channels to supply pharmaceutical companies worldwide. The specific manufacturing sites and supply chains can be complex and may involve multiple intermediate suppliers.

What is the Intellectual Property Landscape for Trandolapril?

The intellectual property (IP) landscape for trandolapril has evolved significantly since its initial development. The expiration of primary patents has opened the market to generic competition, but secondary patents and manufacturing process patents can still influence market entry and production methods.

Key IP Considerations:

• Compound Patents: The fundamental patent protecting the trandolapril molecule itself has long expired. This allowed for the development and introduction of generic versions.
• Formulation Patents: Patents may still exist or have existed for specific formulations of trandolapril, such as sustained-release versions or combination therapies (e.g., with verapamil). These can provide a degree of market exclusivity for certain branded products.
• Manufacturing Process Patents: Companies may hold patents on novel or improved methods for synthesizing trandolapril or its key intermediates. These patents can provide a competitive advantage by offering more efficient, cost-effective, or environmentally friendly production routes. Companies developing new synthesis pathways often seek patent protection for these innovations.
• Polymorph Patents: Different crystalline forms (polymorphs) of an active pharmaceutical ingredient can exhibit different physical properties, such as solubility and stability. Patents may be granted for specific, advantageous polymorphs.
• Combination Therapy Patents: As mentioned, trandolapril is often used in fixed-dose combinations. Patents may protect these specific combinations, their indications, or novel delivery methods for such combinations.

Patent Expirations and Generic Entry:

The core patent for trandolapril expired in the early 2000s. This event triggered the entry of generic competitors, significantly reducing the price of the drug and increasing patient access. However, ongoing patent filings related to manufacturing processes and specific formulations can continue to shape the competitive dynamics. Companies must conduct thorough freedom-to-operate (FTO) analyses to ensure their manufacturing processes and product offerings do not infringe on existing, valid patents.

What are the Regulatory Requirements for Trandolapril Manufacturing?

The manufacturing of trandolapril, like all pharmaceutical products, is subject to stringent regulatory oversight by health authorities worldwide. Compliance with these regulations is mandatory for all suppliers to ensure the safety, efficacy, and quality of the drug.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to current GMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP covers all aspects of production, including personnel, premises, equipment, documentation, raw material control, process validation, quality control, and distribution.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers of trandolapril API typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies seeking to use the API in their finished drug products can reference these filings in their own marketing authorization applications.
• Site Inspections: Regulatory agencies conduct periodic inspections of manufacturing sites to verify GMP compliance. Failure to meet standards can result in warning letters, import alerts, or the inability to supply the market.
• Quality Control and Testing: Rigorous testing is required at various stages of production to ensure the API meets predefined specifications for identity, purity, potency, and absence of impurities. This includes analytical method validation.
• Impurity Profiling: Regulatory guidelines require thorough identification, quantification, and control of impurities, including process-related impurities, degradation products, and residual solvents.
• Stability Studies: Manufacturers must conduct stability studies to determine the shelf-life of the API under various storage conditions.
• Environmental, Health, and Safety (EHS) Regulations: Manufacturing processes must comply with all applicable EHS regulations to protect workers and the environment.

Suppliers must maintain comprehensive documentation and robust quality systems to meet these multifaceted regulatory demands. The ability to consistently meet these standards is a primary differentiator among suppliers.

What are the Key Considerations for Sourcing Trandolapril API?

Sourcing trandolapril API requires a detailed evaluation of potential suppliers to ensure a reliable, high-quality, and cost-effective supply chain. Several factors are critical for pharmaceutical companies making these sourcing decisions.

Key Sourcing Factors:

• Quality and Regulatory Compliance:
  • GMP Certification: Verification of current GMP compliance through recent inspection reports and certifications.
  • Regulatory Filings: Availability of a comprehensive DMF/ASMF and a history of successful regulatory reviews.
  • Quality Agreements: Establishment of detailed quality agreements outlining responsibilities, specifications, change control, and audit rights.
  • Impurity Profile: Understanding the supplier's impurity profile and its comparability to accepted standards or originator data.
• Manufacturing Capacity and Reliability:
  • Production Volume: Ability to meet current and projected demand, including potential scale-up capabilities.
  • Contingency Planning: Supplier's preparedness for disruptions (e.g., raw material shortages, equipment failures, geopolitical issues).
  • Lead Times: Realistic and consistent lead times for order fulfillment.
  • Supply Chain Transparency: Visibility into the supplier's upstream supply chain for critical raw materials.
• Cost and Commercial Terms:
  • Pricing: Competitive pricing that reflects market conditions and the supplier's cost structure.
  • Payment Terms: Favorable payment terms.
  • Contractual Stability: Long-term supply agreements that offer price stability and volume commitments.
• Technical Expertise and Support:
  • Process Understanding: Demonstrated expertise in trandolapril synthesis and analytical methods.
  • Technical Support: Availability of technical support for troubleshooting, process optimization, and regulatory inquiries.
  • Innovation: Potential for process improvements or cost reductions through supplier innovation.
• Geopolitical and Risk Factors:
  • Geographic Location: Diversification of supply sources to mitigate geopolitical risks.
  • Country-Specific Regulations: Awareness of any specific import/export regulations or trade barriers.
  • Ethical Sourcing: Supplier's adherence to ethical labor practices and environmental standards.

A thorough due diligence process, often involving site audits and detailed technical and commercial evaluations, is essential before committing to a supplier.

What are the Key Challenges in the Trandolapril Supply Chain?

The global supply chain for trandolapril faces several challenges that can impact availability, quality, and cost. These challenges require proactive management and strategic planning by all stakeholders.

Key Supply Chain Challenges:

• Raw Material Volatility: Fluctuations in the availability and cost of key starting materials and intermediates used in trandolapril synthesis can lead to price volatility and supply disruptions. These raw materials are often sourced globally, making the supply chain susceptible to geopolitical events, trade disputes, or unforeseen production issues at supplier sites.
• Regulatory Scrutiny: Increasing regulatory expectations regarding impurity control, data integrity, and supply chain traceability can place significant compliance burdens on manufacturers. New or updated regulations may require costly process modifications or enhanced analytical testing.
• Quality Deviations and Recalls: Any deviation from GMP standards or quality specifications can lead to batch rejections, product recalls, and significant reputational damage. Ensuring consistent quality across multiple manufacturing sites and global distribution networks is a constant challenge.
• Competition and Price Pressures: The highly competitive generic market for trandolapril exerts constant downward pressure on prices. Suppliers must continually optimize their manufacturing processes to remain cost-competitive while maintaining high-quality standards.
• Intellectual Property Disputes: While primary patents have expired, disputes over secondary patents (e.g., manufacturing processes, polymorphs) can still arise, potentially leading to litigation and market access restrictions for some suppliers.
• Geopolitical Instability and Trade Barriers: Global events, such as pandemics, natural disasters, or political conflicts, can disrupt transportation routes, impact labor availability, and lead to the imposition of trade barriers, affecting the seamless flow of goods.
• Environmental Sustainability Demands: Increasing pressure from regulators and consumers to adopt more sustainable manufacturing practices, reduce waste, and minimize environmental impact requires investment in greener technologies and processes.

Addressing these challenges requires robust risk management strategies, strong supplier relationships, continuous process improvement, and adherence to evolving regulatory standards.

Key Takeaways

• Trandolapril, an ACE inhibitor for hypertension and heart failure, has a mature market driven by generic competition following the expiration of core compound patents.
• Key suppliers include originator Abbott Laboratories and a broad base of generic API and finished dosage form manufacturers such as Lupin, Dr. Reddy's, Sun Pharma, Aurobindo, and Cipla.
• The IP landscape is characterized by expired compound patents but may still include secondary patents on formulations, manufacturing processes, and polymorphs, necessitating freedom-to-operate analyses.
• Manufacturing is governed by stringent GMP regulations from global authorities (FDA, EMA), requiring comprehensive DMFs/ASMFs and rigorous quality control.
• Sourcing API involves critical evaluation of quality, regulatory compliance, manufacturing capacity, cost, technical support, and geopolitical risk factors.
• The trandolapril supply chain faces challenges from raw material volatility, regulatory scrutiny, quality deviations, price pressures, IP disputes, geopolitical instability, and environmental sustainability demands.

FAQs

1. Are there any active patents that could prevent generic trandolapril production? While the primary compound patent has expired, secondary patents related to specific manufacturing processes, polymorphs, or fixed-dose combinations may still be in force. A thorough freedom-to-operate analysis is required to assess potential infringement risks for any given manufacturing route or formulation.
2. What is the typical shelf-life for trandolapril API? The typical shelf-life for trandolapril API, determined through stability studies, usually ranges from two to five years when stored under recommended conditions. Specific shelf-life claims are detailed in the supplier's product specifications and Drug Master Files.
3. How do regulatory agencies like the FDA ensure the quality of trandolapril API? The FDA ensures API quality through a multi-faceted approach including review of Drug Master Files (DMFs), mandatory GMP inspections of manufacturing facilities, and post-market surveillance. Manufacturers must demonstrate compliance with current Good Manufacturing Practices (cGMP) for all aspects of production and quality control.
4. What are the main impurities to monitor in trandolapril API manufacturing? Key impurities to monitor include process-related impurities (residual starting materials, reagents, by-products), degradation products formed during storage, and residual solvents. Regulatory guidelines like ICH Q3A and Q3C provide frameworks for identifying, qualifying, and controlling these impurities.
5. Can I source trandolapril API from multiple suppliers to mitigate risk? Yes, sourcing from multiple qualified suppliers is a common strategy to mitigate supply chain risks. This approach can help ensure continuity of supply in case of disruption from one supplier, provide competitive pricing, and allow for comparative quality assessments. However, each supplier must undergo rigorous qualification.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs—Impurities in Drug Substances. Retrieved from [FDA Website] (Note: Specific URL varies; reference would typically point to the relevant current guidance document on FDA.gov).

[2] European Medicines Agency. (n.d.). Guideline on the chemistry of new drug substances. Retrieved from [EMA Website] (Note: Specific URL varies; reference would typically point to the relevant current guideline on EMA.europa.eu).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guidelines for Residual Solvents Q3C(R8).

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). Impurities: Guidelines for New Drug Substances Q3A(R11).

[5] Knoll Pharmaceuticals. (1996). Mavik (trandolapril) Prescribing Information. Abbott Laboratories. (Note: Specific historical product labeling details may be found in historical drug compendia or via FDA's FDA.gov archives).